Search results
Results from the WOW.Com Content Network
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor ...
The objective of this study was to compare different tumor markers and their diagnostic value. The tumor markers tested in this experiment were CA 19-9, CA 242 and CEA tumor markers. The data revealed that although each marker have its own level of specificity and correspond to a cancer, all three makers together increase diagnostic value. [7]
[47] [48] Both these markers are associated with the number of tumor cells present in the blood, and as such, are hoped to provide a surrogate for tumor progression and metastasis. However, significant barriers to their adoption include the difficulty of enriching, identifying, and measuring CTC and miRNA levels in blood.
Carbohydrate antigen 19-9 (CA19-9), also known as sialyl-Lewis A, is a tetrasaccharide which is usually attached to O-glycans on the surface of cells. It is known to play a role in cell-to-cell recognition processes. It is also a tumor marker used primarily in the management of pancreatic cancer. [1]
However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers. [3] CEA are glycosyl phosphatidyl inositol (GPI) cell-surface-anchored glycoproteins whose specialized sialo fucosylated glycoforms serve as functional colon ...
Since CD19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia , and chronic lymphocytic leukemia . [8] The majority of B cell malignancies express normal to high levels of CD19.
Blood tests that measure levels of prostate-specific antigen (PSA) were once broadly recommended for all men older than 50. ... types based on genetic mutations in the cancer cells, how the cells ...
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]